Literature DB >> 10406095

High cytoplasmic expression in E. coli, purification, and in vitro refolding of a single chain Fv antibody fragment against the hepatitis B surface antigen.

L Sánchez1, M Ayala, F Freyre, I Pedroso, H Bell, V Falcón, J V Gavilondo.   

Abstract

A single-chain Fv (scFv) antibody fragment against the hepatitis B surface antigen (HBsAg) was expressed in Escherichia coli in the form of two independent fusion proteins, with either 60 ('long') or 27 ('short') amino acid N-terminal encoding sequences related to human interleukin-2. Both fusion proteins were expressed insolubly and at high levels in the bacterial cytoplasm (approximately 30% of total bacterial protein in MM294 cells at a laboratory scale). When recombinant cells were cultured in 5-1 fermentors, expression and optical density increased 2- and 4-fold, respectively, compared to a previous periplasmic insoluble version of the same anti HBsAg scFv. After extraction and solubilization in urea, the cytoplasmic scFvs were purified using immobilized metal ion affinity chromatography, followed by DTT treatment, and refolding by dialysis against a basic pH buffer containing EDTA. The refolded scFvs recognized the recombinant HBsAg in ELISA. Results of an ELISA where antigen affinity chromatography repurified scFvs were used as standards, indicated that refolding efficiencies were high: 56.2% for the 'short' fusion scFv, and 50.6% for the 'long' fusion scFv. Corrected final yields of active scFv were 30.3 and 27.3 mg l-1, respectively, for the aforementioned fusion proteins, 5-6 times better than those reported for the periplasmic scFv variant.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10406095     DOI: 10.1016/s0168-1656(99)00036-x

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  10 in total

1.  High affinity mouse-human chimeric Fab against hepatitis B surface antigen.

Authors:  Biplab Bose; Navin Khanna; Subrat K Acharya; Subrata Sinha
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

2.  Generation and characterization of high affinity humanized fab against hepatitis B surface antigen.

Authors:  Ashutosh Tiwari; Durgashree Dutta; Navin Khanna; Subrat K Acharya; Subrata Sinha
Journal:  Mol Biotechnol       Date:  2009-03-27       Impact factor: 2.695

3.  Anti-FLT3 nanoparticles for acute myeloid leukemia: Preclinical pharmacology and pharmacokinetics.

Authors:  Mincheol Park; Vijaya Pooja Vaikari; Albert T Lam; Yong Zhang; John Andrew MacKay; Houda Alachkar
Journal:  J Control Release       Date:  2020-05-16       Impact factor: 9.776

4.  Expression of a single-chain Fv antibody fragment specific for the hepatitis B surface antigen in transgenic tobacco plants.

Authors:  Nadia Ramírez; Marta Ayala; Damaryst Lorenzo; Daniel Palenzuela; Lissett Herrera; Vivian Doreste; Marlene Pérez; Jorge V Gavilond; Pedro Oramas
Journal:  Transgenic Res       Date:  2002-02       Impact factor: 2.788

5.  Solubility of disulfide-bonded proteins in the cytoplasm of Escherichia coli and its "oxidizing" mutant.

Authors:  Sheng Xiong; Yi-Fei Wang; Xiang-Rong Ren; Bing Li; Mei-Ying Zhang; Yong Luo; Ling Zhang; Qiu-Ling Xie; Kuan-Yuan Su
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

6.  Construction, expression, purification, refold and activity assay of a specific scFv fragment against foot and mouth disease virus.

Authors:  Cao ShengFeng; Lu Ping; Suen Tao; Wang Xin; Wang GuoFeng
Journal:  Vet Res Commun       Date:  2003-04       Impact factor: 2.459

7.  Studies of single-chain antibody expression in quiescent Escherichia coli.

Authors:  K J Mukherjee; D C D Rowe; N A Watkins; D K Summers
Journal:  Appl Environ Microbiol       Date:  2004-05       Impact factor: 4.792

8.  A conjugate of an anti-midkine single-chain variable fragment to doxorubicin inhibits tumor growth.

Authors:  Shuli Zhao; Guangfeng Zhao; Hao Xie; Yahong Huang; Yayi Hou
Journal:  Braz J Med Biol Res       Date:  2012-01-26       Impact factor: 2.590

9.  Tat peptide-mediated soluble expression of the membrane protein LSECtin-CRD in Escherichia coli.

Authors:  Guofu Dong; Changzhen Wang; Yonghong Wu; Jianbo Cong; Li Cheng; Mingqun Wang; Pengkai Zhao; Li Tang; Chenggang Zhang; Ke Wu
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

10.  Assessment of the evolution of cancer treatment therapies.

Authors:  Manuel Arruebo; Nuria Vilaboa; Berta Sáez-Gutierrez; Julio Lambea; Alejandro Tres; Mónica Valladares; Africa González-Fernández
Journal:  Cancers (Basel)       Date:  2011-08-12       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.